Drug Profile
Research programme: pain therapeutics - Apeiron Biologics
Alternative Names: APN 601Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Apeiron Biologics
- Class Small molecules
- Mechanism of Action Kv channel-interacting protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Pain
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Pain in Germany
- 22 Feb 2010 Preclinical development is ongoing
- 22 Feb 2010 The programme is available for partnership (www.apeiron-biologics.com)